Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein

Journal of Nuclear Medicine

Volumn 54, Issue 6, 2013, Pages 961-968

  Orlova, Anna ^a   Jonsson, Andreas ^b   Rosik, Daniel ^b   Lundqvist, Hans ^c   Lindborg, Malin ^d   Abrahmsen, Lars ^d   Ekblad, Caroline ^d   Frejd, Fredrik Y ^c,d   Tolmachev, Vladimir ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d Affibody AB   (Sweden)

Author keywords

Affibody molecule; Albumin; HER2; Targeting therapy

Indexed keywords

ABY 027; ABY 027 IN 111; ABY 027 LU 177; AFFIBODY MOLECULE; ALBUMIN BINDING DOMAIN FUSION PROTEIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYBRID PROTEIN; INDIUM 111; LUTETIUM 177; TETRAXETAN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BINDING AFFINITY; BIOENGINEERING; CARBOXY TERMINAL SEQUENCE; CELL STRAIN; CELL STRAIN SKOV 3; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY PARENCHYMA; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOISOTOPE THERAPY; TUMOR XENOGRAFT;

EID: 84878659182     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.110700     Document Type: Article

References (34)

1. Carlsson J. Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors. Tumour Biol. 2012;33:653-659.
2. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676-3685.
3. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene. 2007;26:3637-3643. (Pubitemid 46842713)
4. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol. 2009;13:235-244.
5. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med. 2005;46(suppl 1):4S-12S. (Pubitemid 47619013)
6. Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 2010;40:122-135.
7. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med. 2005;46(suppl 1):115S-127S. (Pubitemid 47619027)
8. Jain M, Venkatraman G, Batra SK. Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Clin Cancer Res. 2007;13:1374-1382. (Pubitemid 46450425)
9. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201-212. (Pubitemid 28130048)
10. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8:2861-2871.
11. Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006;66:4339-4348.
12. Nygren P-Å. Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J. 2008;275:2668-2676. (Pubitemid 351678678)
13. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584:2670-2680.
14. 68Ga-labeled affibody molecules. J Nucl Med. 2010;51:892-897.
15. Orlova A, Tolmachev V, Pehrson R, et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 2007;67:2178-2186. (Pubitemid 46424237)
16. HER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med. 2007;19:285-291.
17. 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007;67:2773-2782.
18. Tolmachev V, Wållberg H, Andersson K, Wennborg A, Lundqvist H, Orlova A. The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy. Eur J Nucl Med Mol Imaging. 2009;36:1460-1468.
19. Dennis MS, Jin H, Dugger D, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res. 2007;67:254-261. (Pubitemid 46142782)
20. Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132:171-183.
21. Jonsson A, Dogan J, Herne N, Abrahmsén L, Nygren PA. Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng Des Sel. 2008;21:515-527. (Pubitemid 352019923)
22. Feldwisch J, Tolmachev V, Lendel C, et al. Design of an optimized scaffold for affibody molecules. J Mol Biol. 2010;398:232-247.
23. 111In]ABY-025 metastatic detection capability in females with metastatic breast cancer [abstract]. J Nucl Med. 2012;53(suppl 1):220.
24. Ahlgren S, Orlova A, Wållberg H, et al. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med. 2010;51:1131-1138.
25. Tolmachev V, Tran TA, Rosik D, Sjöberg A, Abrahmsén L, Orlova A. Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. J Nucl Med. 2012;53:953-960.
26. HER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm. 2008;23:435-442.
27. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22:701-706. (Pubitemid 38702826)
28. Adams GP, Shaller CC, Dadachova E, et al. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res. 2004;64:6200-6206. (Pubitemid 39136232)
29. Zahnd C, Kawe M, Stumpp MT, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res. 2010;70:1595-1605.
30. Vaneycken I, Devoogdt N, Van Gassen N, et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J. 2011;25:2433-2446.
31. Andersen JT, Pehrson R, Tolmachev V, Daba MB, Abrahmsén L, Ekblad C. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem. 2011;286:5234-5241.
32. 111In labeled Herceptin. Nucl Med Biol. 2002;29:599-606.
33. Hoppmann S, Miao Z, Liu S, et al. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting. Bioconjug Chem. 2011;22:413-421.
34. 111In radiolabels. J Nucl Med. 2001;42:1281-1287.